Table 1.
Detail of the vaccine type, route of administration, dose, time of challenge and protection status of pigs’ sera used in this report.
| Vaccine Type, Dose, and Route of Administration * | Challenge at dpv † | Number of Protected/ Total at Challenge †† |
|---|---|---|
| ASFV-G-Δ9GL/ΔUK (IM) 102 HAD | 28 | 3/9 |
| ASFV-G-Δ9GL/ΔUK (IM) 104 HAD | 28 | 13/15 |
| ASFV-G-Δ9GL/ΔUK (IM) 106 HAD | 28 | 15/15 |
| ASFV-G-Δ9GL/ΔUK (IM) 104 HAD | 7 | 1/5 |
| ASFV-G-Δ9GL/ΔUK (IM) 104 HAD | 14 | 5/5 |
| ASFV-G-Δ9GL/ΔUK (IM) 104 HAD | 21 | 4/5 |
| ASFV-G-ΔI177L (IM) 102 HAD | 28 | 20/20 |
| ASFV-G-ΔI177L (IM) 106 HAD | 28 | 5/5 |
| ASFV-G-ΔI177L (O/N) 106 HAD | 28 | 5/5 |
* IM: intramuscular; ON: oronasal. HAD: Hemadsorption. † dpv: days post vaccination. †† Clinical observation was performed for 21 days after challenge.